Navigation Links
NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
Date:6/10/2009

complete enrollment, analyze the data, and submit an NDA amendment prior to the assigned PDUFA date. Submission of this amendment during the review cycle may result in an extension of the PDUFA date.

Anthony DiTonno, CEO of NeurogesX, commented, "With the FDA's approval of our protocol, we believe we can quickly complete the requested study and submit an amendment to our NDA. We are hopeful to submit this additional data before our PDUFA date and that any delay in the FDA's decision will be relatively short. We are optimistic that an FDA decision on our NDA may be available before the end of 2009. On the heels of our European approval, we are optimistic about the potential for a near-term announcement of an EU commercial partnership and we look forward to the potential for a Qutenza launch in Europe and potentially the U.S. in the first half of 2010."

About NeurogesX, Inc.

NeurogesX (NASDAQ: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. NeurogesX submitted a new drug application (NDA) for Qutenza to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and was given a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.

Neur
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014 Not long ago, it was ... be performed late in the development cycle – even ... regulatory trends suggest that, like many things GxP, expectations ... recent years, multiple drug sponsors have been required by ... questions during phase I/II. It’s not only clinical trial ...
(Date:8/19/2014)... NJ (PRWEB) August 20, 2014 ... and regenerative medicine is an inadequate vascular supply. ... constructs and decellularized tissues is critical for successful ... have attempted to mitigate deficiencies in vascularization and ... adding scaffold bioactivity, optimizing scaffold design and architecture, ...
(Date:8/19/2014)... 19, 2014 Research and Markets  has announced ... - Global Strategic Business Report" report to their offering. ... Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The report ... , Europe , Asia-Pacific ... are provided for the period 2012 through 2020. Market data ...
(Date:8/19/2014)... 2012, the European Union (EU) mandated use of the ICH-recommended ... – responding to the increasing need to understand and manage ... many regions, the main objectives of the PBRER are to:, ... of new or emerging information on the risks of a ... potential benefits of a drug; and , Allow ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... , Integrated system simplifies and improves Northern blot ... , Streamline RNA analysis with a whole host of ... total RNA miniprep kit is,used to isolate ample ... RNA is ready to use in a number of ...
... Improve reliability of PCR reactions with Herculase ... Holly Hogrefe ,Stratagene , Stratagene recently released ... novel enzyme formulation that provides,superior performance in both ... Herculase DNA polymerase exhibits greater fidelity than,commercial DNA ...
... still video system to directly acquire,images from chemiluminescent ... ,Stratagene , The Eagle Eye II ... of chemiluminescent Western blots. The light-tight cabinet is ... chemiluminescent signals. Also,the systems charge-coupled device (CCD) camera ...
Cached Biology Technology:Tools for Detecting MSH2 Expression in Chinese Hamster Ovary Cells 2Tools for Detecting MSH2 Expression in Chinese Hamster Ovary Cells 3Tools for Detecting MSH2 Expression in Chinese Hamster Ovary Cells 4Tools for Detecting MSH2 Expression in Chinese Hamster Ovary Cells 5Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR,Performance 2Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR,Performance 3Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR,Performance 4Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR,Performance 5Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR,Performance 6Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR,Performance 7Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR,Performance 8Imaging Chemiluminescent Western Blots 2Imaging Chemiluminescent Western Blots 3
(Date:8/20/2014)... In a study of 158 pregnant teenagers in Rochester, ... and intentional consumption of ice, cornstarch, vacuum dust, baby ... new Cornell study. , Moreover, such teens had significantly ... not eat nonfood substances. , Pregnant teens, regardless of ... can lead to iron deficiency and anemia. Low iron ...
(Date:8/20/2014)... Arizona State University, the Wellcome Trust Sanger Institute and ... isolated Mycobacterium pinnipedii from skeletons found in ... pathogen is a relative of the TB bacterium that ... today. These researchers assume that seals carried the pathogens ... sea lions was unexpected" comments Sebastien Gagneux, from the ...
(Date:8/20/2014)... the Oklahoma Medical Research Foundation a five-year, $14.5 million ... bacteria,s effects on humans. , For 10 years, ... studied the human immune response to anthrax bacteria as ... original funding came soon after anthrax-laced letters killed five ... attacks of Sept. 11, 2001. , The long-term ...
Breaking Biology News(10 mins):Pica in pregnant teens linked to low iron 2$14.5 million grant awarded to continue anthrax studies 2
... PROVIDENCE, RI An injury to the anterior cruciate ... While it can often be corrected through surgery, the ... joint diseases, including osteoarthritis (OA). The problem is that ... is impacted by the trauma of the injury and ...
... in the United States as a result of trauma and ... bone fusion but with limited mechanical strength often due to ... harvest without pain and severe morbidity. Funded by the National ... of Chemistry, Chemical Biology and Biomedical Engineering at Stevens Institute ...
... to whether we will likely succeed or fail at a ... levels of neural effort put forth in movement-planning circuits in ... neuroscientists at the California Institute of Technology (Caltech). ... James G. Boswell Professor of Neuroscience at Caltechappears in the ...
Cached Biology News:Lubricating the knee cartilage after ACL repair may prevent osteoarthritis 2Lubricating the knee cartilage after ACL repair may prevent osteoarthritis 3NSF funds innovative approach to biomimetic nanofiber bone regeneration 2NSF funds innovative approach to biomimetic nanofiber bone regeneration 3Caltech: Gain and loss in optimistic versus pessimistic brains 2Caltech: Gain and loss in optimistic versus pessimistic brains 3
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... Dot Blot Kits overcome this limitation and ... a wide range in low-density protein array ... They are ideal for performing reverse-phase protein ... for the presence of low abundant antigens. ...
AC input: 50-60 Hz230 V...
... arraying proteins of interest with sensitive ... DiscoverLight Protein Array Kits allow for ... lysate or antibody in a low-density ... designed nitrocellulose membranes with a 384-grid ...
Biology Products: